Skip to content

more news

It’s with great pleasure that Aspire officially welcome our new CEO, Richard Condon, to the company. Richard joins us from Bayer UK and as we embark on the next chapter, his leadership, knowledge, and experience, is a welcome addition to the team at a time we say a big thank you to the driving force behind Aspire Pharma, its founder, Graham Fraser-Pye. Graham’s vision for the company and the subsequent dedication and hard work to make it happen, saw us arrive at this point, and as he transitions into the new role of Chairman of the Aspire board, the company is positioned to build on these foundations and accelerate again. Richard commented;

“It is an honour and a privilege to be asked to lead such a rapidly growing and important business with an agenda for growth, and a talented and focussed team to deliver it. I am excited about my new role as CEO, and strongly believe in our mission – be agile to opportunity, unconstrained by market segment, with products that make a valuable difference to patients and payors.  I am thrilled to be part of writing the next chapter in our organisations story, and look forward to being part of, and learning from, such an amazing team. Exciting times!”

Aspire Pharma Continues LCCC’s Medical Centre Sponsorship

Aspire Pharma Continues LCCC’s Medical Centre Sponsorship Leicestershire County Cricket Club (LCCC) is delighted to announce Aspire Pharma Ltd as the new sponsor of the club’s state-of-the-art medical centre at
Read More

Aspire Pharma acquires Morningside Pharmaceuticals and Morningside Healthcare and its subsidiaries, including Morningside Healthcare (India) creating the UK’s premier Speciality Pharma company

Aspire Pharma acquires Morningside Pharmaceuticals and Morningside Healthcare and its subsidiaries, including Morningside Healthcare (India) creating the UK’s premier Speciality Pharma company Petersfield, Hampshire, October 3rd 2022, Aspire Pharma Limited,
Read More

Global Licensing rights builds Aspire’s strategic commitment to develop therapies in the prevention of bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) in preterm infants

Aspire Pharma Ltd, (Petersfield Hampshire), today announced the successful completion of its global licensing agreement of Retinolx , owned by Orphanix GmbH, a privately held, clinical-stage biopharmaceutical company focussed on the
Read More

You are now leaving the Aspire website and being directed to an external website for which Aspire is not responsible.